Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection

Liver International

Volumn 35, Issue s1, 2015, Pages 56-64

  Asselah, Tarik ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Daclatasvir; Dasabuvir; Direct acting antivirals; Elbasvir; Grazoprevir; Ledipasvir; Ombitasvir; Paritaprevir; Sofosbuvir

Indexed keywords

ANTIVIRAL AGENTS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL NONSTRUCTURAL PROTEINS;

ANTAGONISTS AND INHIBITORS; DISEASE ERADICATION; DRUG EFFECTS; DRUG THERAPY, COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; METHODS; TRENDS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DISEASE ERADICATION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84919683888     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12745     Document Type: Review

References (33)

1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatol 2002; 36(5 Suppl. 1): S47-56.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88-102.
4. Lohmann V, Korner F, Koch J, et al. Replication of sub- genomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
5. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-4.
6. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-55.
7. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 463-7.
8. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
9. Asselah T, Bièche I, Mansouri A, et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol 2010; 221: 264-74.
10. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-81.
11. Estrabaud E, Lapalus M, Broët P, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol 2014; 88: 6394-402.
12. Lamarre D, Anderson PC, Bailey M, et al. An NS3 prote- ase inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
13. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
14. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
15. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014; 15: 121-30.
16. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
17. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011; 54: 1069-72.
18. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatol 2010; 51: 1122-6.
19. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
20. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
21. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
23. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
24. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
25. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
26. Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? J Hepatol 2014; 61: 1430-3.
27. Poordad F, Sievert W, Mollison L, et al. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir for non-cirrhotic patients with chronic HCV genotype 1 infection: unity-1 phase 3 SVR12 results. Hepatology, 2014; 60: 1271A-1272A.
28. Muir AJ, Poordad F, Lalezari J, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: unity-2 phase 3 SVR12 results. Hepatology, 2014; 60: 1267A-1268A.
29. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; doi: 10.1016/S0140-6736(14)61793-1.
30. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without rivavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; doi: 10.1016/S0140-6736(14)61795-5.
31. Lawitz E, Poordad F, Gutierrez JA, et al. C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + sofosbuvir in treatment-naive patients with hepatitis C Virus Genotype 1 Infection, with and without cirrhosis, for durations of 4, 6, or 8 Weeks (Interim Results). Hepatology 2014; 60: 1286A-1287A.
32. Asselah T, Perumalswami PV, Dieterich D. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. Liver Int 2014; 34: 1447-51.
33. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.